Literature DB >> 9623639

Allopregnanolone in women with premenstrual syndrome.

M Bicíková1, L Dibbelt, M Hill, R Hampl, L Stárka.   

Abstract

5Alpha-reduced metabolites of progesterone, especially 3alpha-hydroxy-5alpha-pregnan-20-one (allopregnanolone) are now listed to neurosteroids. Their anesthetic properties can be explained by their allosteric interaction with GABA(A) receptors. A woman's organism is provided with an abundance of progesterone during the luteal phase of the menstrual cycle and its level falls down sharply with the first day of menses. The level of allopregnanolone follows that of progesterone. Many women suffer from so called premenstrual syndrome (PMS) during the luteal phase. In this study we have determined allopregnanolone and progesterone levels and their ratios in order to assess the over-all activity of C21-steroid 5alpha-reductase in these patients and in controls. Significantly lower levels of both progesterone and allopregnanolone than in controls have been found in PMS patients in the follicular phase only.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623639     DOI: 10.1055/s-2007-978871

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  23 in total

Review 1.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 2.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 3.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

4.  Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder.

Authors:  M Bicíková; J Tallová; M Hill; Z Krausová; R Hampl
Journal:  Neurochem Res       Date:  2000-12       Impact factor: 3.996

Review 5.  Allopregnanolone as a mediator of affective switching in reproductive mood disorders.

Authors:  Crystal Edler Schiller; Peter J Schmidt; David R Rubinow
Journal:  Psychopharmacology (Berl)       Date:  2014-05-21       Impact factor: 4.530

6.  Effects of a naturally occurring neurosteroid on GABAA IPSCs during development in rat hippocampal or cerebellar slices.

Authors:  E J Cooper; G A Johnston; F A Edwards
Journal:  J Physiol       Date:  1999-12-01       Impact factor: 5.182

7.  Pharmacokinetic and behavioral effects of allopregnanolone in healthy women.

Authors:  Erika Timby; Matts Balgård; Sigrid Nyberg; Olav Spigset; Agneta Andersson; Joanna Porankiewicz-Asplund; Robert H Purdy; Di Zhu; Torbjörn Bäckström; Inger Sundström Poromaa
Journal:  Psychopharmacology (Berl)       Date:  2005-09-21       Impact factor: 4.530

Review 8.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Brain steroidogenesis mediates ethanol modulation of GABAA receptor activity in rat hippocampus.

Authors:  Enrico Sanna; Giuseppe Talani; Fabio Busonero; Maria Giuseppina Pisu; Robert H Purdy; Mariangela Serra; Giovanni Biggio
Journal:  J Neurosci       Date:  2004-07-21       Impact factor: 6.167

Review 10.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.